198 related articles for article (PubMed ID: 24753077)
21. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
22. [Nab-paclitaxel].
Lopez-Trabada Ataz D; Dumont S; André T
Bull Cancer; 2015 Jun; 102(6):568-76. PubMed ID: 26008630
[TBL] [Abstract][Full Text] [Related]
23. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
[TBL] [Abstract][Full Text] [Related]
24. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
Montero AJ; Adams B; Diaz-Montero CM; Glück S
Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779
[TBL] [Abstract][Full Text] [Related]
25. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
[TBL] [Abstract][Full Text] [Related]
26. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
[TBL] [Abstract][Full Text] [Related]
27. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
[TBL] [Abstract][Full Text] [Related]
28. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Lipp HP
Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
[TBL] [Abstract][Full Text] [Related]
29. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
30. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
31. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
32. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Hirsh V
Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
[TBL] [Abstract][Full Text] [Related]
33. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Guo W; Tang XD; Tang S; Yang Y
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(12):805-8. PubMed ID: 16889724
[TBL] [Abstract][Full Text] [Related]
36. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Chirgwin J; Chua SL
Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
[TBL] [Abstract][Full Text] [Related]
37. Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.
Chatterjee M; Ben-Josef E; Robb R; Vedaie M; Seum S; Thirumoorthy K; Palanichamy K; Harbrecht M; Chakravarti A; Williams TM
Cancer Res; 2017 Nov; 77(21):5925-5937. PubMed ID: 28923854
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
Ciruelos E; Jackisch C
Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
